Amhis Nawal, Carignan Julie, Tai Lee-Hwa
Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.
Department of Surgery, Division of General Surgery, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Mol Ther Oncol. 2024 Jun 8;32(3):200825. doi: 10.1016/j.omton.2024.200825. eCollection 2024 Sep 19.
Pancreaticobiliary cancer, encompassing malignancies of both the pancreatic and biliary tract, presents a formidable clinical challenge marked by a uniformly bleak prognosis. The asymptomatic nature of its early stages often leads to delayed detection, contributing to an unfavorable 5-year overall survival rate. Conventional treatment modalities have shown limited efficacy, underscoring the urgent need for alternative therapeutic approaches. In recent years, immunotherapy has emerged as a promising avenue in the fight against pancreaticobiliary cancer. Strategies such as therapeutic vaccines and the use of tumor-infiltrating lymphocytes have garnered attention for their potential to elicit more robust and durable responses. This review seeks to illuminate the landscape of emerging immunotherapeutic interventions, offering insights from both clinical and research perspectives. By deepening our understanding of pancreaticobiliary cancer and exploring innovative treatment modalities, we aim to catalyze improvements in patient outcomes and quality of life.
胰胆管癌,包括胰腺和胆道的恶性肿瘤,是一个严峻的临床挑战,其预后普遍不佳。早期无症状的特点常常导致检测延迟,使得5年总生存率不理想。传统治疗方式疗效有限,凸显了对替代治疗方法的迫切需求。近年来,免疫疗法已成为对抗胰胆管癌的一条有前景的途径。治疗性疫苗和使用肿瘤浸润淋巴细胞等策略因其引发更强有力和持久反应的潜力而受到关注。本综述旨在阐明新兴免疫治疗干预措施的情况,从临床和研究角度提供见解。通过加深我们对胰胆管癌的理解并探索创新治疗方式,我们旨在推动患者预后和生活质量的改善。